A 38-year-old woman with a history of recurrent vulvovaginal candidiasis (4 episodes in the past 12 months) presents with vulval pruritus, thick white vaginal discharge, and a positive vaginal KOH mount. She has no systemic illness, normal immune function, and is not on antibiotics. She was treated with fluconazole 150 mg single dose 6 weeks ago for her last episode. What is the most appropriate management strategy for this patient?

Explanation

## Clinical Diagnosis The patient has recurrent vulvovaginal candidiasis (RVVC), defined as ≥4 symptomatic episodes in 12 months. She has normal immune function and is not on prolonged antibiotics, making this idiopathic RVVC. ## Definition and Epidemiology of RVVC **Key Point:** Recurrent vulvovaginal candidiasis (RVVC) occurs in 5–8% of women of reproductive age. It is most commonly caused by *Candida albicans* and is associated with host factors (genetic predisposition, local immune response) rather than antimicrobial resistance. **High-Yield:** RVVC is managed in two phases: (1) **acute episode treatment** with a short course of azole, and (2) **maintenance/suppressive therapy** with low-dose fluconazole for 6 months to reduce recurrence risk. ## Treatment Algorithm for RVVC ```mermaid flowchart TD A[Recurrent VVC: ≥4 episodes/year]:::outcome --> B{Acute episode?}:::decision B -->|Yes| C[Acute treatment:<br/>Fluconazole 150 mg × 1<br/>OR Itraconazole 200 mg BD × 1 day]:::action C --> D[After acute cure]:::outcome D --> E[Maintenance suppression:<br/>Fluconazole 100-150 mg daily<br/>for 6 months]:::action E --> F[Reassess after 6 months]:::decision F -->|Symptom-free| G[Discontinue;<br/>monitor for recurrence]:::outcome F -->|Recurrence| H[Extend suppression<br/>or consider azole resistance]:::action ``` ## Comparison of Antifungal Regimens for RVVC | Regimen | Indication | Dosing | Duration | Evidence | | --- | --- | --- | --- | --- | | **Fluconazole 150 mg × 1** | Acute episode | Single dose | One-time | First-line for acute VVC | | **Fluconazole 100 mg daily** | Maintenance/suppression | Daily oral | 6 months | Gold standard for RVVC; reduces recurrence by 50–90% | | **Itraconazole 200 mg BD × 1 day** | Acute episode (alternative) | 200 mg twice daily | 1 day | Alternative if fluconazole intolerant | | **Clotrimazole 500 mg vaginal** | Acute episode (topical) | Single vaginal tablet | One-time | Effective but lower systemic levels; not ideal for RVVC | ## Why Fluconazole 100 mg Daily for 6 Months? **Clinical Pearl:** Long-term suppressive therapy with low-dose fluconazole (100–150 mg daily) is the evidence-based standard for RVVC. It reduces recurrence risk by 50–90% and is well-tolerated. The patient should be counselled that: - Suppression is continued for 6 months after the acute episode is cured - After 6 months, therapy is stopped and the patient is monitored for recurrence - If recurrence occurs, suppression may be restarted or extended **Mnemonic: RVVC Management — "ACUTE then MAINTAIN"** - **A**cute episode: Fluconazole 150 mg × 1 (or itraconazole) - **C**ure confirmed: Symptoms resolve - **U**se suppression: Fluconazole 100 mg daily - **T**reat for: 6 months - **E**valuate: Reassess after 6 months - **M**aintain: Monitor for recurrence after stopping ## Addressing the Patient's History The patient was treated 6 weeks ago with fluconazole 150 mg (acute dose), which is appropriate for a single episode. However, because she has had 4 episodes in 12 months, she now meets criteria for RVVC and requires **maintenance suppressive therapy** to prevent further recurrences. **Warning:** Do not repeat single-dose fluconazole for each episode in RVVC — this is reactive, not preventive. Suppressive therapy is the standard of care. ## Monitoring and Follow-Up 1. Confirm cure of the current acute episode (symptoms resolve, typically within 3–7 days) 2. Initiate fluconazole 100 mg daily for 6 months 3. At 6 months, discontinue and monitor for recurrence 4. If recurrence occurs, consider: - Repeat suppression for 6–12 months - Evaluation for risk factors (diabetes, hormonal contraceptives, sexual practices) - Azole susceptibility testing if resistance is suspected